Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey.

NCT06265363 · tracked via the Priya Life Science Turkey tracker

Sponsor

Baskent University Ankara Hospital

Phase

Observational

Started

2023-08-01

Last updated

2024-11-01

Condition(s) studied

Retinopathy of Prematurity

Study summary

The study includes preterm infants who are being screened for ROP between August 1,2023 and August 1, 2024 in 94 neonatal intensive care units (NICUs) in Turkey. Infants with birth weight (BW) of \>1500 g or ≥ 33 weeks' gestation who are screened for retinopathy of prematurity are included. The incidence of any ROP, severe ROP and treatment modalities will be determined. The risk factors for ROP development will also be evaluated.

Eligibility

Sex

ALL

Min age

28 Days

Max age

—

Healthy volunteers

Inclusion Criteria: * Infants with BW \>1500 g or ≥33 weeks' gestation who were determined to be at risk for ROP by the attending clinician and were screened for ROP. Exclusion Criteria: * Neonates who died before the first ROP examination are excluded from the study.

Primary outcome measure(s)

Incidence of ROP — 12 months
Incidence of ROP and severe ROP in infants \> 1500 gr and gestational age ≥ 33 weeks in Turkey.

Trial sites (1)

Facility	City	Region	Status
Baskent University	Ankara	Turkey (Türkiye)	Recruiting

More Baskent University Ankara Hospital trials in Turkey

Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study Recruiting

Other trials for the same condition

Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity Recruiting

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next) Active, not recruiting

European Disease Registry on Retinopathy of Prematurity (ROP) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06265363 on ClinicalTrials.gov ↗ ← All trials in Turkey